Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on CRISPR-based therapies, has announced its upcoming second quarter 2024 earnings call. The conference call is scheduled for August 8, 2024, at 8 a.m. ET. During this call, the company will present its Q2 2024 financial results and provide operational highlights.
Investors and interested parties can join the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will also be available. A replay of the call will be accessible through Intellia's website after 12 p.m. ET on the same day.
Intellia Therapeutics (NASDAQ:NTLA), una delle principali aziende di editing genetico in fase clinica focalizzata sulle terapie basate su CRISPR, ha annunciato la prossima chiamata per i risultati finanziari del secondo trimestre 2024. La conferenza è programmata per l'8 agosto 2024 alle 8:00 ET. Durante questa chiamata, l'azienda presenterà i suoi risultati finanziari del Q2 2024 e fornirà risultati operativi.
Gli investitori e le parti interessate possono partecipare alla chiamata componendo il numero 1-833-316-0545 (USA) o 1-412-317-5726 (internazionale). Sarà disponibile anche un webcast dal vivo. Una registrazione della chiamata sarà accessibile attraverso il sito web di Intellia dopo le 12:00 ET dello stesso giorno.
Intellia Therapeutics (NASDAQ:NTLA), una de las principales compañías de edición genética en etapa clínica centradas en terapias basadas en CRISPR, ha anunciado su próxima llamada de resultados financieros del segundo trimestre de 2024. La conferencia está programada para el 8 de agosto de 2024 a las 8 a.m. ET. Durante esta llamada, la empresa presentará sus resultados financieros del Q2 2024 y proporcionará puntos destacados operativos.
Los inversores y partes interesadas pueden unirse a la llamada marcando el 1-833-316-0545 (EE.UU.) o 1-412-317-5726 (internacional). También habrá un webcast en vivo. Una repetición de la llamada estará disponible a través del sitio web de Intellia después de las 12 p.m. ET del mismo día.
인텔리아 테라퓨틱스(NASDAQ:NTLA)는 CRISPR 기반 치료에 초점을 맞춘 주요 임상 단계 유전자 편집 회사로서, 다가오는 2024년 2분기 실적 발표 전화 회의를 발표했습니다. 회의는 2024년 8월 8일 오전 8시 ET로 예정되어 있습니다. 이 전화 회의에서 회사는 2024년 2분기 재무 결과와 운영 주요 내용을 발표할 것입니다.
투자자와 관심 있는 당사자는 1-833-316-0545 (미국) 또는 1-412-317-5726 (국제)로 전화를 걸어 회의에 참여할 수 있습니다. 실시간 웹캐스트도 제공될 예정입니다. 회의의 재생 콘텐츠는 같은 날 정오 ET 이후 인텔리아 웹사이트를 통해 접근할 수 있습니다.
Intellia Therapeutics (NASDAQ:NTLA), une entreprise de édition génique en phase clinique de premier plan spécialisée dans les thérapies basées sur CRISPR, a annoncé sa prochaine conférence de résultats financiers du deuxième trimestre 2024. L'appel est prévu pour le 8 août 2024 à 8h00 ET. Lors de cet appel, l'entreprise présentera ses résultats financiers du Q2 2024 et fournira des points saillants opérationnels.
Les investisseurs et les parties intéressées peuvent rejoindre l'appel en composant le 1-833-316-0545 (États-Unis) ou le 1-412-317-5726 (international). Un webinaire en direct sera également disponible. Un enregistrement de l'appel sera accessible via le site d'Intellia après 12h00 ET le même jour.
Intellia Therapeutics (NASDAQ:NTLA), ein führendes Unternehmen in der klinischen Phase für Gen-Editing, das sich auf CRISPR-basierte Therapien konzentriert, hat seine bevorstehende Ergebnispräsentation für das zweite Quartal 2024 angekündigt. Die Konferenzschaltung ist für den 8. August 2024 um 8 Uhr ET angesetzt. Während dieses Anrufs wird das Unternehmen seine finanziellen Ergebnisse für das Q2 2024 präsentieren und operative Höhepunkte darlegen.
Investoren und Interessierte können an dem Anruf teilnehmen, indem sie 1-833-316-0545 (USA) oder 1-412-317-5726 (international) wählen. Ein Live-Webcast wird ebenfalls verfügbar sein. Eine Wiederholung des Anrufs wird am selben Tag nach 12 Uhr ET über die Website von Intellia zugänglich sein.
- Intellia Therapeutics is holding an earnings call, indicating transparency and communication with investors
- The company continues to focus on developing CRISPR-based therapies, maintaining its position in the gene editing field
- None.
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on August 8, 2024, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
ian.karp@intelliatx.com
Lina Li
Senior Director, Investor Relations and Corporate Communications
lina.li@intelliatx.com
FAQ
When is Intellia Therapeutics (NTLA) releasing its Q2 2024 earnings?
How can investors join Intellia Therapeutics' (NTLA) Q2 2024 earnings call?
What will be discussed in Intellia Therapeutics' (NTLA) upcoming earnings call?
Where can I find a replay of Intellia Therapeutics' (NTLA) Q2 2024 earnings call?
